HUBEI PROVINCE, CHINA--(MARKET WIRE)--Sep 18, 2007 -- Benda Pharmaceutical, Inc. ("Benda" or the "Company") (OTC BB:BPMA.OB - News), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as Gendicine®, the world's first commercialized gene therapy medicine for the treatment of cancer, has unveiled the dramatic improvements to its Gendicine® distribution system that resulted in Benda subsidiary SiBiono's recently reported 128% quarter on quarter revenue increase. The Company also provides the following information on the approximate number of patients benefiting from Gendicine®:
